ANSWER: B

Rationale:

Renin-mediated cleavage of angiotensinogen to angiotensin I is the rate-limiting step of the RAAS cascade because renin is the only enzyme capable of catalyzing this reaction, and its secretion from juxtaglomerular cells is the primary regulated point controlling overall RAAS activity; all downstream products are generated in direct proportion to renin activity, making renin secretion the principal determinant of angiotensin II and aldosterone levels.

• Option A: Option A is incorrect because ACE (angiotensin-converting enzyme), which converts angiotensin I to angiotensin II, is not rate-limiting; ACE is constitutively expressed in high concentrations on pulmonary and vascular endothelium and is not a regulated control point in the cascade.
• Option C: Option C is incorrect because AT1 receptor binding by angiotensin II is a downstream effector step, not a biosynthetic control point; receptor occupancy does not determine the rate of angiotensin II generation.
• Option D: Option D is incorrect because aminopeptidase A cleavage of angiotensin II to angiotensin III is a degradative pathway rather than a rate-limiting biosynthetic step, and angiotensin III has weaker cardiovascular effects than angiotensin II.
• Option E: Option E is incorrect because aldosterone release from the adrenal cortex is a downstream consequence of angiotensin II action at AT1 receptors and is not the regulated point controlling the rate of the overall cascade.

ANSWER: D

Rationale:

ACE (also known as kininase II) is a zinc metallopeptidase with two principal endogenous substrates: angiotensin I, which it cleaves to angiotensin II (the primary vasoconstrictor of the RAAS), and bradykinin, which it inactivates by sequential cleavage of C-terminal dipeptides; ACEi block both reactions simultaneously because they share a single active site, so ACE inhibition reduces angiotensin II generation (therapeutic cardiovascular benefit) while also prolonging bradykinin half-life in tissues, with accumulated bradykinin mediating cough via B2 receptor activation on airway C-fibers and angioedema via increased vascular permeability.

• Option A: Option A is incorrect because ACE does not convert angiotensin II to angiotensin III; that reaction is performed by aminopeptidase A, and while ACE does degrade substance P, the clinically dominant bradykinin accumulation effect is omitted.
• Option B: Option B is incorrect because renin, not ACE, converts angiotensinogen to angiotensin I; ACE acts one step downstream on angiotensin I.
• Option C: Option C is incorrect because while ACE does convert angiotensin I to angiotensin II and does degrade substance P, the pharmacologically dominant second substrate causing the class-defining adverse effects of cough and angioedema is bradykinin, not substance P.
• Option E: Option E is incorrect because ACE does not degrade norepinephrine; catecholamine degradation is performed by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO), not by ACE.

ANSWER: A

Rationale:

Captopril is unique among ACE inhibitors in being both orally administered and pharmacologically active without requiring hepatic biotransformation; it directly coordinates the zinc ion at the ACE active site via its sulfhydryl (-SH) group, which distinguishes it chemically from the majority of ACEi (enalapril, ramipril, perindopril, lisinopril) that use a carboxylate group as the zinc-coordinating moiety, and from fosinopril, which uses a phosphonate group.

• Option B: Option B is incorrect because captopril is not a prodrug; it is enalapril (converted to enalaprilat) and ramipril (converted to ramiprilat) that are the archetypal ester prodrugs requiring hepatic hydrolysis, while lisinopril is also active as administered.
• Option C: Option C is incorrect because captopril uses a sulfhydryl group, not a phosphonate group; fosinopril uses the phosphonate zinc-coordinating moiety, and it does not have the highest ACE affinity — ramiprilat holds that distinction among the active diacids.
• Option D: Option D is incorrect because captopril uses a sulfhydryl group, not a carboxylate group; the carboxylate zinc ligand is the feature shared by enalaprilat, lisinopril, ramiprilat, perindoprilat, and most other class members.
• Option E: Option E is incorrect because captopril does not require hepatic activation and there is no metabolite called captoprilat; captopril is itself the active drug, making this the defining pharmacokinetic distinction of captopril within the class.

ANSWER: C

Rationale:

ACEi-induced cough is caused by bradykinin accumulation in pulmonary tissues; because ACE (kininase II) is one of the two principal enzymes responsible for bradykinin degradation, its inhibition extends bradykinin half-life and raises local concentrations at vascular and airway surfaces; accumulated bradykinin activates B2 receptors on airway sensory C-fibers, triggering arachidonic acid release via phospholipase A2, which generates prostaglandin E2 (PGE2) and thromboxane A2 (TXA2); these eicosanoids sensitize the cough reflex arc by lowering the threshold of bronchial afferent fibers, producing the characteristic dry, non-productive cough that does not respond to antihistamines or antitussives.

• Option A: Option A is incorrect because ACE inhibitors do not directly inhibit prostaglandin synthesis; they do not inhibit cyclooxygenase (COX) enzymes, and in fact the mechanism operates in the opposite direction, increasing eicosanoid generation through bradykinin-mediated phospholipase A2 activation.
• Option B: Option B is incorrect because angiotensin II at AT1 receptors does not play a primary role in bronchial mucus clearance, and reduced Ang II is the intended therapeutic effect of ACEi, not the mechanism of cough; cough is bradykinin-mediated, not angiotensin II-mediated.
• Option D: Option D is incorrect because while ACE does degrade substance P, the primary mediator of ACEi cough is bradykinin accumulation, not substance P; furthermore, substance P does not trigger mast cell histamine release as the dominant cough pathway, and antihistamines are clinically ineffective for ACEi cough, which would not be the case if histamine were the principal mediator.
• Option E: Option E is incorrect because angiotensin I does not activate AT2 receptors; AT1 and AT2 receptors bind angiotensin II, not angiotensin I, and angiotensin I accumulation proximal to the ACE block is not recognized as a clinically significant mechanism of cough.

ANSWER: E

Rationale:

ACEi-induced angioedema is a bradykinin-mediated reaction caused by accumulation of bradykinin secondary to loss of ACE (kininase II)-mediated bradykinin degradation; accumulated bradykinin acts on B2 receptors on vascular endothelium, increasing vascular permeability and causing the non-pitting, non-pruritic, urticaria-free edema that characteristically involves the tongue, lips, periorbital region, and larynx; because histamine is not the mediator, antihistamines (H1 blockers) and corticosteroids are ineffective, and epinephrine provides only transient vasoconstriction without reversing the underlying bradykinin-driven permeability increase; icatibant (30 mg subcutaneously), a competitive B2 receptor antagonist, is the targeted pharmacological intervention, and fresh frozen plasma (FFP), which contains functional ACE and carboxypeptidase N capable of degrading accumulated bradykinin, is a reasonable alternative when icatibant is unavailable.

• Option A: Option A is incorrect because ACEi angioedema is bradykinin-mediated, not IgE-mediated; the absence of urticaria and the non-allergic clinical picture confirm this; epinephrine and diphenhydramine are appropriate for anaphylaxis but not for bradykinin-driven angioedema.
• Option B: Option B is incorrect because ACEi angioedema is not complement-mediated; hereditary angioedema involves C1-esterase inhibitor deficiency, but ACEi angioedema operates through the bradykinin pathway independently of complement activation; FFP is not contraindicated and is in fact a reasonable treatment because it provides bradykinin-degrading enzymes.
• Option C: Option C is incorrect because accumulated angiotensin I is not the pathogenic mediator; the swelling is bradykinin-driven, and switching to an ARB (angiotensin receptor blocker) would not reverse acute angioedema and could itself rarely trigger the same reaction since ARBs do not restore bradykinin degradation.
• Option D: Option D is incorrect because this reaction is not histamine-mediated; the absence of urticaria, the non-pruritic quality, and the failure of antihistamines in clinical practice all distinguish ACEi angioedema from mast cell-driven histaminergic reactions.

ANSWER: B

Rationale:

Fosinopril is unique among ACE inhibitors in that its active form, fosinoprilat, is eliminated via dual pathways — approximately 50% renal and 50% hepatic/biliary — so when renal clearance declines, biliary elimination compensates proportionally, preventing the accumulation that occurs with renally-eliminated agents such as enalaprilat and lisinopril; because of this compensatory mechanism, dose adjustment for fosinopril is not required until creatinine clearance (CrCl) falls below 10 mL/min, compared to the 30 mL/min threshold for most other class members, making it the preferred ACEi in patients with CKD stage 3b through 4.

• Option A: Option A is incorrect because fosinopril does not have the shortest half-life of the class; captopril has the shortest half-life at approximately 2 hours, and a short half-life alone does not prevent accumulation — it is the elimination route, not half-life duration, that determines accumulation risk in renal impairment.
• Option C: Option C is incorrect because fosinopril is itself a prodrug requiring hepatic esterase hydrolysis to generate fosinoprilat; the statement that it does not require hepatic activation is false, and lisinopril is actually the class member that does not require biotransformation.
• Option D: Option D is incorrect because fosinoprilat is not eliminated entirely by the biliary route; it is the approximately equal split between renal and biliary (approximately 50:50) that is the pharmacokinetically distinguishing feature, not exclusive biliary elimination.
• Option E: Option E is incorrect because fosinopril's advantage in renal impairment is based on its dual elimination route, not on plasma protein binding characteristics; the dialyzability of enalaprilat (which is high) is actually a liability, since patients on hemodialysis may require supplemental dosing after each session.

ANSWER: D

Rationale:

In bilateral renal artery stenosis, the reduced perfusion pressure distal to the stenoses means that the kidneys are operating under conditions where glomerular filtration rate (GFR) is maintained by an autoregulatory adaptation: angiotensin II-mediated constriction of the efferent arteriole, which sustains intraglomerular hydrostatic pressure despite the reduced afferent inflow pressure; when an ACE inhibitor is given, angiotensin II generation is suppressed, efferent arteriolar tone is lost, intraglomerular pressure falls precipitously, and GFR may collapse acutely, producing potentially severe acute kidney injury (AKI); the same physiology applies in unilateral RAS with a solitary functioning kidney, as there is no contralateral kidney to compensate.

• Option A: Option A is incorrect because while ACEi do raise renin secretion through loss of Ang II negative feedback, elevated renin does not drive excessive Ang II in this context because ACE is inhibited; furthermore, the mechanism of AKI in bilateral RAS is hemodynamic loss of efferent arteriolar tone, not nephrosclerosis from excess Ang II.
• Option B: Option B is incorrect because ACE inhibitors reduce aldosterone secretion, causing natriuresis and mild volume contraction rather than retention; the contraindication in bilateral RAS is hemodynamic, not related to sodium retention or pressure elevation.
• Option C: Option C is incorrect because afferent arteriolar dilation is not the relevant mechanism; the critical adaptation sustaining GFR in bilateral RAS is efferent arteriolar constriction by Ang II, not afferent dilation, and ACEi do not affect afferent vasodilatory responses.
• Option E: Option E is incorrect because ACE inhibitors cause systemic and renal vasodilation through Ang II reduction, which would reduce, not increase, pressure within the stenotic segment; renal artery rupture is not a recognized clinical consequence of ACEi use.

ANSWER: A

Rationale:

ACE inhibitors are absolutely contraindicated throughout all three trimesters of pregnancy, a point emphasized by both FDA labeling and ACC/AHA guidelines; the risks differ by trimester but are present throughout: first-trimester exposure has been associated with an increased incidence of cardiovascular malformations (ventricular septal defects, patent ductus arteriosus) and CNS malformations in infants based on cohort data, representing a critical period for organogenesis; second and third trimester exposure causes fetal renal tubular dysgenesis through suppression of the fetal RAAS (renin-angiotensin-aldosterone system), which is essential for fetal renal development and amniotic fluid homeostasis; consequences include oligohydramnios (reduced amniotic fluid from fetal anuria), limb contractures from reduced fetal movement space, pulmonary hypoplasia, and neonatal anuria and hypotension that can be fatal; this fetal toxicity is a class effect shared by ARBs.

• Option B: Option B is incorrect because ACEi are contraindicated in all three trimesters, not just from the second trimester onward; first-trimester use is associated with structural malformations, and the concept of a safe first-trimester window for ACEi is not supported by evidence or regulatory guidance.
• Option C: Option C is incorrect because the contraindication applies to all three trimesters; first-trimester exposure carries risk of structural malformations during organogenesis, not just third-trimester renal toxicity.
• Option D: Option D is incorrect because ACEi fetal toxicity is mediated by suppression of the fetal RAAS, not by bradykinin accumulation; and ARBs are equally contraindicated in pregnancy because they also suppress fetal RAAS-dependent renal development through AT1 receptor blockade, making them unsafe alternatives.
• Option E: Option E is incorrect because first-trimester ACEi exposure does warrant additional fetal surveillance including detailed anatomic ultrasound to assess for cardiac and CNS structural abnormalities, and the risk is not limited to the third trimester.

ANSWER: C

Rationale:

The HOPE trial enrolled approximately 9,297 high-cardiovascular-risk patients aged 55 or older who had established cardiovascular disease or diabetes plus at least one additional cardiovascular risk factor, but who did not have heart failure or known reduced ejection fraction; ramipril 10 mg daily reduced the composite primary endpoint of MI (myocardial infarction), stroke, and cardiovascular death by approximately 22% relative to placebo; the degree of blood pressure reduction observed was modest (approximately 3/2 mmHg mean difference), and the magnitude of cardiovascular benefit exceeded what could be attributed to blood pressure lowering alone, leading investigators to propose additional vascular protective mechanisms including bradykinin-mediated endothelial effects, nitric oxide generation, and anti-inflammatory actions of bradykinin at B2 receptors.

• Option A: Option A is incorrect because the HOPE trial specifically excluded patients with known heart failure or low ejection fraction; the trials that established ACEi as foundational therapy in HFrEF (heart failure with reduced ejection fraction) were CONSENSUS and SOLVD, which used enalapril, not ramipril; and the HOPE benefit was not attributed entirely to blood pressure reduction.
• Option B: Option B is incorrect because HOPE enrolled patients without established heart failure, and the primary endpoint was a composite of MI, stroke, and CV death, not heart failure hospitalization; prevention of left ventricular remodeling was studied in post-MI trials such as SAVE (captopril) and AIRE (ramipril).
• Option D: Option D is incorrect because the Lewis trial, not HOPE, established ACEi renoprotection in type 1 diabetic nephropathy; the Lewis trial used captopril and enrolled patients with type 1 diabetes and macroproteinuria, demonstrating reduction in progression to end-stage renal disease.
• Option E: Option E is incorrect because HOPE compared ramipril versus placebo, not two doses of ramipril; the trial did not have a dose-comparison design, and its primary outcome was the cardiovascular composite in high-risk patients, not a post-MI dose-finding study.

ANSWER: E

Rationale:

Lisinopril is a lysine analog of enalaprilat that is itself orally active — no prodrug conversion is required — distinguishing it from enalapril, which must be hydrolyzed by hepatic esterases to the active diacid enalaprilat before it can bind the ACE active site; lisinopril's oral bioavailability is approximately 25% (unaffected by food), and it is eliminated entirely by renal excretion of unchanged drug with a plasma half-life of approximately 12 hours; because lisinopril has no hepatic metabolic pathway, it accumulates progressively as GFR (glomerular filtration rate) declines, and dose reduction is required when creatinine clearance (CrCl) falls below 30 mL/min, with further reduction needed in CrCl below 10 mL/min.

• Option A: Option A is incorrect because lisinopril is not a prodrug; it is pharmacologically active as administered without hepatic conversion; it is enalapril (not lisinopril) that is the archetypal ester prodrug requiring hepatic activation, and the description in this option has the two drugs' pharmacokinetic profiles reversed.
• Option B: Option B is incorrect because lisinopril is not hepatically metabolized; it is eliminated entirely as unchanged drug by the kidney, making it a drug that accumulates in renal impairment rather than being protected by hepatic clearance; enalaprilat (the active form of enalapril) is also renally eliminated and requires dose adjustment in renal impairment.
• Option C: Option C is incorrect because neither lisinopril nor enalapril share the same prodrug pathway — lisinopril requires no activation while enalapril does — and lisinopril's plasma half-life is approximately 12 hours, not 36 hours; no ACEi is dosed once weekly.
• Option D: Option D is incorrect because lisinopril does not have dual hepatic-renal elimination; it is exclusively renally excreted; it is fosinopril that has the dual hepatic/biliary and renal elimination pathway that prevents accumulation in renal impairment.

ANSWER: B

Rationale:

Aliskiren binds directly and competitively to the active site of renin, preventing renin from cleaving angiotensinogen to angiotensin I, which is the rate-limiting biosynthetic step of the RAAS; because aliskiren suppresses the entire downstream cascade simultaneously (reducing Ang I, Ang II, and aldosterone), and because angiotensin II normally exerts negative feedback on renin secretion from juxtaglomerular cells, the reduction in Ang II by aliskiren should theoretically increase renin secretion — but because renin activity is directly blocked by aliskiren at its catalytic site, plasma renin activity (PRA) falls despite the removal of feedback inhibition; this distinguishes aliskiren fundamentally from ACE inhibitors and ARBs, which block downstream steps and thereby remove Ang II-mediated negative feedback on renin, causing a compensatory and measurable rise in PRA that can partially limit their effectiveness and is associated with increased angiotensin I and renin protein levels.

• Option A: Option A is incorrect because aliskiren does not raise PRA; it reduces PRA by directly occupying the renin active site; the reactive PRA rise is characteristic of ACEi and ARBs, not of the direct renin inhibitor.
• Option C: Option C is incorrect because aliskiren acts at the renin step — the first and rate-limiting step of the RAAS — not at ACE; aliskiren does not directly vasodilate independent of RAAS and does not act downstream of renin.
• Option D: Option D is incorrect because aliskiren reduces PRA from the outset of treatment; there is no initial PRA rise followed by suppression; the biphasic PRA response described does not characterize either aliskiren or ACE inhibitor pharmacology as encountered clinically.
• Option E: Option E is incorrect because aliskiren does not convert angiotensin I to angiotensin II — that is the function of ACE; and ACE inhibitors do not suppress renin secretion via prostaglandins; the elevated PRA seen with ACEi reflects removal of Ang II negative feedback on juxtaglomerular renin release.

ANSWER: A

Rationale:

The ALTITUDE trial enrolled patients with type 2 diabetes and CKD (chronic kidney disease) or cardiovascular disease who were already receiving an ACEi or ARB, and randomized them to add aliskiren or placebo; the trial was terminated early for harm: the aliskiren combination arm showed significantly increased rates of AKI (acute kidney injury), hyperkalemia, hypotension, and stroke without any reduction in cardiovascular or renal endpoints, resulting in a regulatory contraindication against combining aliskiren with ACEi or ARBs in patients with diabetes; the ONTARGET trial, which compared telmisartan alone, ramipril alone, and the combination in high-cardiovascular-risk patients, found that the combination arm produced higher rates of AKI, hyperkalemia, and hypotension than either monotherapy arm without improving the primary cardiovascular composite endpoint, and the combination arm had higher rates of dialysis requirement than ramipril alone, collectively establishing that dual ACEi-ARB therapy offers no cardiovascular benefit while significantly increasing renal and hemodynamic adverse effects.

• Option B: Option B is incorrect because ALTITUDE did not demonstrate mortality benefit from DRI-ACEi combinations; it was terminated early for harm in that arm; the characterization of a beneficial DRI-ACEi and harmful ACEi-ARB distinction does not reflect the actual trial findings, which showed harm from both combination approaches.
• Option C: Option C is incorrect because ONTARGET did not demonstrate superiority of the combination over monotherapy for the primary cardiovascular composite; the combination arm performed no better for cardiovascular outcomes and was associated with more adverse renal and hemodynamic events; ALTITUDE was terminated early for harm, not benefit.
• Option D: Option D is incorrect because neither trial established dual RAAS blockade as safe or recommended for diabetic nephropathy; both demonstrated harm from combination therapy, and current guidelines specifically advise against routine ACEi-ARB combination use based in part on these trial results.
• Option E: Option E is incorrect because ALTITUDE enrolled patients with type 2 diabetes (not type 1) who were already on ACEi or ARB (not aliskiren monotherapy), and ONTARGET specifically evaluated the combination of telmisartan plus ramipril as one of its three arms, making dual RAAS blockade a central focus of the trial design.

ANSWER: D

Rationale:

NSAIDs (non-steroidal anti-inflammatory drugs) including ibuprofen inhibit cyclooxygenase (COX) enzymes in the renal afferent arteriole and macula densa, reducing synthesis of prostaglandin E2 (PGE2) and prostacyclin (PGI2); these prostaglandins normally maintain afferent arteriolar dilation and support renal perfusion, particularly in states of reduced effective arterial volume such as heart failure, CKD, or diuretic use where the kidney relies on this prostaglandin-mediated vasodilation to preserve GFR against reduced perfusion pressure; simultaneously, lisinopril (an ACEi) suppresses angiotensin II generation, reducing efferent arteriolar constriction; the combination of reduced afferent dilation (NSAID effect) and reduced efferent constriction (ACEi effect) dramatically lowers the intraglomerular pressure gradient, collapsing GFR and producing hemodynamic AKI; this interaction is especially dangerous in elderly patients with CKD, heart failure, or volume depletion, all of which are present in this patient.

• Option A: Option A is incorrect because lisinopril is not metabolized by CYP3A4; it is renally excreted unchanged and has no hepatic metabolic pathway; ibuprofen does not increase lisinopril plasma concentrations via enzyme inhibition.
• Option B: Option B is incorrect because the primary mechanism of this interaction is hemodynamic reduction of intraglomerular pressure rather than direct tubular toxicity; while NSAIDs can cause interstitial nephritis with chronic use, the acute creatinine rise in this scenario reflects hemodynamic AKI from the dual afferent-efferent pressure collapse.
• Option C: Option C is incorrect because ibuprofen does not increase AT1 receptor sensitivity or cause efferent arteriolar constriction; NSAIDs reduce afferent arteriolar dilation (by blocking prostaglandins on the afferent side), not increase efferent resistance; and the combined effect reduces rather than elevates intraglomerular pressure.
• Option E: Option E is incorrect because NSAIDs do not cause hypokalemia by blocking mineralocorticoid receptors; they may in fact contribute to hyperkalemia by reducing aldosterone via COX inhibition of prostaglandin-mediated aldosterone secretion; potassium disturbance is not the mechanism of the hemodynamic AKI in this interaction.

ANSWER: C

Rationale:

ACE inhibitors reduce angiotensin II generation, and angiotensin II is the primary stimulus for aldosterone secretion from the zona glomerulosa of the adrenal cortex; with reduced aldosterone, the principal cells of the cortical collecting duct have reduced expression and activity of the epithelial sodium channel (ENaC) on the luminal membrane and reduced sodium-potassium ATPase on the basolateral membrane; this diminishes the electrochemical gradient (the lumen-negative potential generated by sodium reabsorption through ENaC) that normally drives passive potassium secretion through luminal ROMK (renal outer medullary potassium) channels into the tubular fluid; the result is reduced urinary potassium excretion and rising serum potassium; spironolactone competitively blocks the mineralocorticoid receptor in the same principal cells, preventing any residual aldosterone from activating ENaC and sodium-potassium ATPase, compounding the reduction in potassium secretion; in patients with CKD, the reduced nephron mass further limits the total capacity for potassium excretion, making the combination of ACEi plus MRA (mineralocorticoid receptor antagonist) particularly prone to clinically significant hyperkalemia.

• Option A: Option A is incorrect because ACE inhibitors do not increase proximal tubular potassium reabsorption; the proximal tubule is not the primary site of regulated potassium handling; and spironolactone acts on the mineralocorticoid receptor in the collecting duct, not on a proximal tubular transporter.
• Option B: Option B is incorrect because ACE inhibitors cause efferent arteriolar dilation (by reducing Ang II), which lowers intraglomerular pressure rather than increasing it; while this can modestly reduce GFR, the primary mechanism of hyperkalemia is through aldosterone suppression at the collecting duct, not hemodynamic reduction in filtered potassium load.
• Option D: Option D is incorrect because there is no enzyme that converts potassium to a renally excreted form; potassium is excreted as the potassium ion itself, not as a metabolite requiring enzymatic conversion; and spironolactone acts on mineralocorticoid receptors, not on H-K-ATPase, which is the acid-secreting pump in intercalated cells and is distinct from potassium secretory mechanisms in principal cells.
• Option E: Option E is incorrect because bradykinin accumulation from ACE inhibition does not directly regulate collecting duct potassium channels; the hyperkalemia mechanism operates through aldosterone suppression, not through bradykinin-mediated ion channel modulation.

ANSWER: E

Rationale:

ACEi-induced angioedema is driven by bradykinin accumulation at B2 receptors on vascular endothelium; bradykinin, not histamine, is the mediator of the increased vascular permeability and tissue edema, which explains why antihistamines (H1 blockers such as diphenhydramine) are ineffective, why corticosteroids (which suppress IgE-mediated and complement-mediated inflammation) do not help, and why epinephrine produces at most transient benefit through vasoconstriction without reversing the underlying bradykinin-driven permeability increase; icatibant, a selective competitive antagonist at the bradykinin B2 receptor (30 mg subcutaneously), directly blocks the mediator responsible for the vascular permeability increase and is the targeted pharmacological treatment; fresh frozen plasma (FFP) is a reasonable alternative because it contains functional ACE and carboxypeptidase N, both of which can degrade accumulated bradykinin, though its onset of action is slower.

• Option A: Option A is incorrect because tachyphylaxis to epinephrine does not explain the treatment failure here; the failure reflects a mechanistic mismatch, not a pharmacokinetic limitation of epinephrine; H2 blockade with ranitidine addresses histamine at gastric and vascular H2 receptors but does not affect bradykinin-mediated permeability.
• Option B: Option B is incorrect because ACEi angioedema is not caused by C1-esterase inhibitor deficiency; hereditary angioedema (HAE) involves inherited C1 inhibitor deficiency, and while C1-esterase inhibitor concentrate is appropriate for HAE attacks, it is not the standard intervention for ACEi-induced angioedema, which is a bradykinin pathway disorder not involving complement component deficiency.
• Option C: Option C is incorrect because this reaction is bradykinin-mediated, not IgE-mediated; the absence of urticaria and the failure of standard anaphylaxis treatments confirm the non-IgE mechanism; omalizumab targets free IgE and is used for chronic spontaneous urticaria, not for acute bradykinin-mediated angioedema.
• Option D: Option D is incorrect because corticosteroid dose escalation and leukotriene receptor antagonists are not effective for bradykinin-mediated angioedema; montelukast blocks cysteinyl leukotriene receptors, which are not the mediators responsible for ACEi angioedema; continuing ineffective treatment while laryngeal swelling progresses creates serious airway risk.

ANSWER: B

Rationale:

Enalapril is the archetypal ester prodrug ACE inhibitor; after oral absorption (bioavailability approximately 60%, unaffected by food), hepatic esterases hydrolyze the ethyl ester bond to release enalaprilat, the pharmacologically active diacid that binds the ACE zinc active site via a carboxylate moiety; enalaprilat has a biphasic plasma half-life — an initial elimination phase of approximately 2 hours followed by a prolonged terminal phase of approximately 11 hours reflecting tight tissue ACE binding — supporting twice-daily to once-daily dosing; enalaprilat is eliminated almost entirely by renal excretion, so it accumulates progressively as GFR (glomerular filtration rate) declines; dose reduction is required when creatinine clearance (CrCl) falls below 30 mL/min; enalaprilat is removed by hemodialysis, meaning patients on intermittent hemodialysis may require a supplemental dose after each dialysis session to maintain ACE inhibition between sessions, a clinically important pharmacokinetic consideration that differs from lisinopril (also dialyzable) and from fosinopril (which does not accumulate in renal impairment).

• Option A: Option A is incorrect because enalapril is activated by hepatic esterases, not renal esterases; the conversion occurs in the liver after oral absorption, not in the kidney after filtration; hepatic esterase activity is generally preserved in CKD, so activation is not impaired in renal disease.
• Option C: Option C is incorrect because enalapril activation occurs predominantly in the liver through hepatic esterases, not in intestinal mucosa during first-pass absorption; while some intestinal conversion may occur, the liver is the primary activation site, and the characterization of intestinal mucosal hydrolysis as the dominant pathway is not accurate.
• Option D: Option D is incorrect because enalaprilat does not undergo dual hepatic-biliary elimination; it is primarily renally excreted, which is precisely why dose adjustment is required in renal impairment; fosinoprilat is the class member with balanced dual elimination, and the dose adjustment threshold for fosinopril is CrCl below 10 mL/min, not 30 mL/min.
• Option E: Option E is incorrect because this option has the relationship reversed: enalapril is the prodrug and enalaprilat is the pharmacologically active metabolite, not the other way around; enalapril is the orally administered precursor, and enalaprilat is the form responsible for ACE inhibition.

ANSWER: A

Rationale:

The ALLHAT trial enrolled over 33,000 high-risk hypertensive patients aged 55 or older and compared chlorthalidone (a thiazide-type diuretic) against lisinopril (an ACEi), amlodipine (a calcium channel blocker), and (in a separately terminated arm) doxazosin; for the primary composite endpoint of fatal coronary heart disease (CHD) and nonfatal myocardial infarction (MI), chlorthalidone was at least as effective as lisinopril, demonstrating that a thiazide-type diuretic was not inferior to an ACE inhibitor for the primary cardiovascular outcome in a high-risk population; in the pre-specified subgroup of Black patients, those randomized to lisinopril had significantly higher rates of stroke compared to those randomized to chlorthalidone, a disparity attributed to less effective blood pressure lowering by lisinopril as monotherapy in this population (Black patients tend to have lower renin activity and respond less robustly to RAAS-based monotherapy), rather than to a direct pharmacodynamic disadvantage of the ACEi mechanism; this finding reinforced guideline preferences for thiazide diuretics or calcium channel blockers as initial monotherapy in Black patients with uncomplicated hypertension.

• Option B: Option B is incorrect because lisinopril did not significantly reduce all-cause mortality compared to chlorthalidone in ALLHAT; the trial demonstrated at best equivalence for the primary endpoint, and chlorthalidone was superior or equivalent on several secondary endpoints including heart failure hospitalization; ALLHAT did not establish ACEi superiority over diuretics.
• Option C: Option C is incorrect because the opposite result was observed in the stroke subgroup: Black patients on lisinopril had higher, not lower, stroke rates compared to chlorthalidone; lisinopril is not supported by ALLHAT as preferred for stroke prevention in populations of African ancestry.
• Option D: Option D is incorrect because outcomes were not equivalent across all subgroups; the stroke disparity in Black patients on lisinopril versus chlorthalidone was a key subgroup finding, and chlorthalidone showed advantages over lisinopril on several secondary endpoints including combined CVD and heart failure outcomes.
• Option E: Option E is incorrect because ALLHAT was not terminated early for benefit in the lisinopril arm; the doxazosin arm was terminated early for harm (higher heart failure rates), but the lisinopril arm completed its pre-specified follow-up without a mortality benefit signal.

ANSWER: C

Rationale:

Lithium is handled in the kidney similarly to sodium: it is freely filtered at the glomerulus and approximately 80% is reabsorbed in the proximal tubule via the sodium-hydrogen exchanger (NHE3) and other sodium-coupled transporters, with only modest distal and collecting duct reabsorption; ACE inhibitors such as ramipril suppress aldosterone generation by reducing angiotensin II, and reduced aldosterone decreases ENaC (epithelial sodium channel)-mediated sodium reabsorption in the collecting duct; the kidney compensates for this distal sodium loss by upregulating proximal tubular sodium reabsorption, and because lithium follows the proximal sodium reabsorption pathway, proximal lithium reabsorption increases proportionally, reducing urinary lithium excretion and causing serum lithium accumulation; this interaction is potentiated when ACEi are combined with diuretics, which produce volume contraction and further stimulate proximal sodium (and lithium) reabsorption; the interaction requires serum lithium monitoring within 1–2 weeks of any ACEi initiation or dose change in lithium-maintained patients, and lithium dose reduction will typically be required.

• Option A: Option A is incorrect because lithium is not metabolized by CYP3A4 or any hepatic cytochrome P450 enzyme; lithium is an elemental ion excreted entirely by the kidney without hepatic biotransformation; ramipril is not a clinically significant CYP3A4 inhibitor.
• Option B: Option B is incorrect because ACE inhibitors reduce efferent arteriolar tone and therefore lower intraglomerular pressure rather than raising it; increased filtration does not explain lithium toxicity; the mechanism operates through enhanced reabsorption, not enhanced filtration.
• Option D: Option D is incorrect because lithium excretion is not substantially dependent on active organic cation transport via OCT2; lithium's primary renal clearance mechanism is glomerular filtration followed by variable tubular reabsorption; ACEi do not inhibit OCT2 as a recognized pharmacokinetic mechanism.
• Option E: Option E is incorrect because lithium has negligible plasma protein binding (less than 5%) and is essentially all unbound in plasma; displacement from protein binding is not a pharmacokinetic mechanism relevant to lithium; monitoring of free versus total lithium is not a clinical practice because virtually all serum lithium is already in the free (unbound) state.

ANSWER: D

Rationale:

AT1 receptors are Gq/G11-coupled GPCRs (G protein-coupled receptors) that activate phospholipase C, generate IP3 and DAG, and raise intracellular calcium; they are widely and constitutively expressed in vascular smooth muscle (mediating vasoconstriction), adrenal zona glomerulosa (mediating aldosterone secretion), renal tubular cells (mediating sodium and water reabsorption), and cardiac myocytes and fibroblasts (mediating hypertrophy and fibrosis in chronic activation); AT1 receptor signaling is the primary target of both ACE inhibitors and ARBs (angiotensin receptor blockers) and is responsible for both the pathological cardiovascular effects of angiotensin II and the therapeutic hemodynamic responses blocked by these drugs; AT2 receptors are structurally related but functionally opposing, are predominantly expressed in fetal tissues during development and downregulated postnatally, but are re-expressed and upregulated at sites of injury or stress in adults; AT2 receptor activation generally opposes AT1-mediated effects, promoting vasodilation (via nitric oxide and bradykinin), natriuresis, antiproliferation, and apoptosis, and is increasingly recognized as potentially mediating beneficial aspects of angiotensin signaling at the tissue level.

• Option A: Option A is incorrect because AT1 receptors are Gq-coupled (not Gs-coupled) and operate via phospholipase C and intracellular calcium, not cAMP elevation; the cAMP pathway is characteristic of Gs-coupled receptors such as beta-adrenoceptors and vasopressin V2 receptors.
• Option B: Option B is incorrect because AT2 receptors are not Gq-coupled and do not primarily increase intracellular calcium; AT2 signaling involves inhibitory G proteins (Gi) and phosphotyrosine phosphatases rather than the Gq/PLC/calcium pathway; and AT2 activation does not increase cardiac contractility.
• Option C: Option C is incorrect because it reverses the receptor assignments; it is AT1 receptors, not AT2, that mediate efferent arteriolar constriction, aldosterone secretion, vasoconstriction, and cardiac remodeling; the ACEi-induced loss of efferent arteriolar tone that causes AKI in bilateral RAS is an AT1-mediated effect.
• Option E: Option E is incorrect because AT1 receptors are not expressed exclusively in vascular smooth muscle, and AT2 receptors are not expressed exclusively in the adrenal cortex; both receptors have broad and overlapping tissue distributions; the suggestion that ACEi lower potassium through AT2 receptor blockade is also incorrect — ACEi raise serum potassium by reducing aldosterone through AT1 pathway suppression.

ANSWER: E

Rationale:

Aliskiren has one of the lowest oral bioavailabilities of any approved antihypertensive drug at approximately 2.6%; this poor absorption results from limited intrinsic gastrointestinal permeability compounded by P-glycoprotein (P-gp, also known as MDR1 or ABCB1)-mediated active efflux back into the intestinal lumen, which returns absorbed aliskiren to the gut for elimination before it reaches the portal circulation; high-fat meals significantly reduce aliskiren absorption and should be avoided; aliskiren is a substrate for both P-gp and CYP3A4 in minor metabolic pathways but does not meaningfully inhibit either, so it does not alter the plasma concentrations of co-administered P-gp or CYP3A4 substrates; its plasma half-life is approximately 24 hours, supporting once-daily dosing; the predominant elimination route is hepatobiliary excretion of largely unchanged drug in feces, with only approximately 1–2% recovered in urine — a pharmacokinetic profile that distinguishes it from ACEi (predominantly renal elimination) and means it does not accumulate disproportionately in renal impairment, though pharmacodynamic hyperkalemia and AKI risk apply equally in CKD.

• Option A: Option A is incorrect because aliskiren's oral bioavailability is approximately 2.6%, not 65%; the characterization of high bioavailability is directly opposite to aliskiren's known pharmacokinetic limitation; 65% bioavailability describes enalapril rather than aliskiren.
• Option B: Option B is incorrect because aliskiren is not substantially metabolized by CYP2D6; aliskiren's metabolism is limited and occurs primarily through CYP3A4 in a minor pathway; CYP2D6 polymorphisms are not a clinically relevant consideration for aliskiren dosing.
• Option C: Option C is incorrect because aliskiren is not eliminated entirely by renal excretion; it is predominantly eliminated via the hepatobiliary route in feces with minimal urinary excretion; the half-life is approximately 24 hours, not 6 hours, and twice-daily dosing is not required.
• Option D: Option D is incorrect because aliskiren does not undergo glucuronidation via UGT1A4; the predominant elimination route is hepatobiliary excretion of largely unchanged drug; the half-life of approximately 4 hours described here is incorrect and would require twice-daily dosing inconsistent with aliskiren's clinical pharmacology.

ANSWER: B

Rationale:

The CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study) trial demonstrated that enalapril reduced mortality by 27% in patients with NYHA class IV (severe) HFrEF compared to placebo, with the greatest benefit in mortality from progressive heart failure; the SOLVD treatment trial subsequently demonstrated that enalapril reduced all-cause mortality by 16% and heart failure hospitalizations significantly in patients with mild-to-moderate HFrEF (NYHA class II-III, EF ≤35%), cementing enalapril and the ACEi class as standard of care; the mechanisms underlying the HFrEF mortality benefit extend beyond simple blood pressure reduction to include attenuation of the neurohormonal activation (RAAS and sympathetic nervous system) that drives maladaptive cardiac remodeling, prevention of angiotensin II-mediated cardiac hypertrophy and fibrosis at AT1 receptors, afterload reduction through systemic vasodilation, and potential contributions from bradykinin-mediated vasodilatory and cardioprotective effects.

• Option A: Option A is incorrect because SAVE (captopril) and AIRE (ramipril) are post-MI trials that enrolled patients after acute MI with reduced ejection fraction, not patients with established symptomatic heart failure at rest; SAVE enrolled post-MI patients with asymptomatic LV dysfunction (EF <40%), and AIRE enrolled post-MI patients with clinical evidence of heart failure; these trials established ACEi benefit in the post-MI setting, which overlaps with but is distinct from the foundational HFrEF indication established by CONSENSUS and SOLVD.
• Option C: Option C is incorrect because PARADIGM-HF was the trial that compared sacubitril-valsartan (an ARNI) against enalapril as the active comparator in HFrEF, and enalapril was the control arm reference; PARADIGM-HF demonstrated ARNI superiority over enalapril rather than confirming ACEi as the optimal therapy; aldosterone-mediated fibrosis suppression is a secondary mechanism, not the primary explanation cited for ACEi benefit in HFrEF.
• Option D: Option D is incorrect because RALES and EPHESUS established the role of mineralocorticoid receptor antagonists (spironolactone and eplerenone) in HFrEF, not ACE inhibitors; these trials enrolled patients already on ACEi background therapy, and their results established MRAs as add-on therapy rather than defining the foundational ACEi indication.
• Option E: Option E is incorrect because the ATLAS trial compared high-dose versus low-dose lisinopril and demonstrated a non-significant trend toward reduced mortality with high-dose lisinopril, not a 45% reduction; the trial established that higher ACEi doses reduce hospitalizations but did not demonstrate a statistically significant all-cause mortality benefit of that magnitude.

ANSWER: C

Rationale:

Captopril's oral bioavailability is approximately 65–75% when taken fasting but decreases by approximately 25–35% when taken with food, a clinically significant reduction that produces lower and more variable peak plasma concentrations; the mechanism of this food effect involves delayed gastric emptying and dilution of captopril in the gastric contents, reducing the concentration gradient available for absorption, as well as possible competition from food-derived peptides and amino acids for intestinal uptake mechanisms; because captopril has the shortest half-life of the class (approximately 2 hours) and requires multiple daily dosing for sustained ACE inhibition, consistent pre-meal administration (at least one hour before or two hours after meals) is important for achieving reliable antihypertensive and renoprotective effects; by contrast, lisinopril (approximately 25% bioavailability) and enalapril (approximately 60% bioavailability) have minimal food interactions and can be administered without regard to meals, simplifying adherence and dosing instructions.

• Option A: Option A is incorrect because captopril's bioavailability decreases, not increases, with food intake; administration with food reduces, not enhances, captopril absorption; the instruction to take captopril before meals (not with meals) is the correct clinical guidance.
• Option B: Option B is incorrect because there is no established chronopharmacological recommendation for captopril based on nocturnal renin activity; while some evidence suggests bedtime dosing of antihypertensives may better address early morning blood pressure surges, this is not a captopril-specific or pharmacokinetically defined administration requirement; the food effect, not timing relative to circadian renin release, is the pharmacokinetically important instruction for captopril.
• Option D: Option D is incorrect because captopril's sulfhydryl group does not cause esophageal corrosive injury; the sulfhydryl group is a zinc-coordinating moiety that binds tightly to metal ions, but it does not corrode esophageal mucosa at therapeutic concentrations; the administration instruction for captopril relates to food timing for absorption optimization, not to esophageal protection.
• Option E: Option E is incorrect because the food interaction is not universal across the ACE inhibitor class; it is a captopril-specific pharmacokinetic characteristic; lisinopril and enalapril have oral bioavailabilities that are not meaningfully affected by food co-administration, and the statement that all ACEi require fasting administration is factually incorrect.